Earnings summary
4D Molecular Therapeutics, Inc. Q1 2026 results
Snapshot
4D Molecular Therapeutics, Inc. reported $3M of revenue in Q1 2026, up 21664.3% year over year, with diluted EPS of $-1.01 and an operating margin of -2416.1%.
- Revenue
- $3M
- YoY growth
- +21664.3%
- Diluted EPS
- $-1.01
- Operating margin
- -2416.1%
$3M
Revenue
+21664.3%
YoY growth
$-1.01
Diluted EPS
-2416.1%
Operating margin